Physician profile
John A Strobis
NPI 1356538896
$1,184.86
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $296 · 2021: $700 · 2022: $13.44.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $281.41 | 2019-2021 | |
| Abbvie INC. | $189.53 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $116.39 | 2019-2021 | |
| Amarin Pharma, INC. | $103.48 | 2019-2021 | |
| Eisai INC. | $81.19 | 2020-2021 | |
| Mylan Specialty L.P. | $53.76 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $41.68 | 2020-2021 | |
| Pfizer INC. | $41.63 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $37.63 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.29 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $37.10 | 2019 | |
| Astellas Pharma US INC | $36.28 | 2019 | |
| Genentech USA, INC. | $32.88 | 2021 | |
| Arbor Pharmaceuticals, INC. | $31.63 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $18.81 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $15.98 | 2019 | |
| Allergan, INC. | $14.25 | 2020 | |
| Janssen Pharmaceuticals, INC | $13.94 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Strobis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.